Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

九典制药（300705）公告，公司于近日收到国家药品监督管理局签发的《药物临床试验批准通知书》， 药品名称为PDX-04，注册分类为化药2.2类，拟定适应症为用于治疗痛风性急性发作镇痛。PDX-4为局 部外用制剂，可为该类患者提供新的治疗选择。目前国内外尚无该产品处于临床试验阶段，亦无相关销 售数据。PDX-4获得临床试验资格对公司的财务状况、经营业绩不构成重大影响。 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局签发的《药物临床试验批准通知书》，在完成相关准备工作后将开展临床 试验研究。其相关信息如下： 一、临床试验通知书基本情况 药品名称：PDX-04 注册分类：化药 2.2 类 受理号：CXHL2500288、CXHL2500289（同产品不同规格） 申请人：湖南九典制药股份有限公司 拟定适应症：用于治疗痛风性急性发作镇痛。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 3 月 14 日受理的 PDX-04 符合药品注册的有关要求，同意开展痛风性急性发作 镇痛的临床试验。 二、同类药品的市场状况 PDX-04 用于治疗痛风性急性发作镇痛的药物，目前国内外未有该产 ...

Group 1: Company Overview and Strategy - The company focuses on mergers and acquisitions that align with its strategic development, aiming to enhance its supply chain, technology, market competitiveness, and product pipeline [2] - The company has established a comprehensive sales channel system, particularly in the outpatient market, which has become a new growth engine for performance [3] Group 2: Product Development and Market Potential - The company believes that the market for Loxoprofen Sodium Gel Patch in the outpatient sector has significant growth potential, supported by stable demand for topical patches in retail [4] - The company plans to continue investing in R&D to expand its product line and strengthen its brand "JiuYue" in the transdermal drug delivery field [3] Group 3: Competitive Positioning - Loxoprofen Sodium Gel Patch is a prescription drug effective for osteoarthritis and muscle pain, while the anti-inflammatory patch is an over-the-counter product with different ingredients and indications [5] - The company aims to leverage its complete supply chain to control costs and ensure product quality in response to competitive products gaining approval [2] Group 4: Financial Projections - For 2025, the company expects a revenue growth of 10-20% and a similar increase in net profit excluding non-recurring items [6] - The company warns that its operational plans and sales forecasts are subject to market conditions and other uncertainties, advising investors to remain aware of risks [7] Group 5: Marketing and Promotion Strategies - The company employs a multi-channel strategy for OTC promotion, integrating online and offline channels, and enhancing consumer experience through educational activities [7] - The brand "JiuYue" is positioned to meet diverse consumer needs through differentiated marketing and a varied product portfolio [7]

关于九典转 02 恢复转股的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 1、债券代码：123223 债券简称：九典转02 2、转股期限：2024年3月21日至2029年9月14日 3、暂停转股时间：2025年5月19日至2025年5月23日 4、恢复转股时间：2025年5月26日 特别提示： 湖南九典制药股份有限公司（以下简称"公司"）因实施2024年度权益分派， 根据《湖南九典制药股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》相关规定，自2025年5月19日至2025年5月23日九典转02暂停转股，具体 内容详见公司于巨潮资讯网刊登的《关于实施2024年度权益分派期间九典转02 暂停转股的公告》（公告编号：2025-037）。 根据相关规定，自2024年度权益分派股权登记日后的第一个交易日（即2025 年5月26日）起九 ...

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Lidocaine Gel Patch, indicating a significant regulatory approval for a new product aimed at treating postherpetic neuralgia [1] Group 1: Product Details - The drug is named Lidocaine Gel Patch, classified as a Class 3 chemical drug [1] - The formulation is a patch with dimensions of 14cm x 10cm, containing 14g of gel and 700mg of Lidocaine per patch [1] - The product is specifically indicated for alleviating pain associated with postherpetic neuralgia and is suitable for use on intact skin [1]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-040 | 利多卡因凝胶贴膏由 Teikoku Seiyaku Co., Ltd.开发，1999 年 3 月首次在 美国上市，2024 年 5 月进口至中国上市。该贴膏属镇痛药，用于缓解带状疱疹 后神经痛，用于无破损皮肤。《带状疱疹后神经痛诊疗中国专家共识》明确将利 多卡因凝胶贴膏列为缓解带状疱疹后神经痛的首选外用药物，尤其适用于轻至中 度疼痛或无法耐受口服药物的患者。摩熵数据显示，利多卡因凝胶贴膏 2023 年 在全国医院销售（全终端）和全国药店零售的销售额分别为 10,783.35 万元和 536.49 万元。 2、剂型：贴膏剂 3、规格：每贴（14cm×10cm）含膏量 14g，含利多卡因 700mg 4、注册分类：化学药品 3 类 5、申请事项：药品注册（境内生产） 6、证书编号：2025S01264 湖南九典制药股份有限公司 关于公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 ...

Group 1 - The stock price of Jiutian Pharmaceutical (300705) closed at 16.08 yuan on May 20, 2025, with an increase of 2.03% and a trading volume of 140,200 shares, resulting in a transaction amount of 225 million yuan [1] - The company has a comprehensive layout in the fields of chemical drug formulations, raw materials, pharmaceutical excipients, traditional Chinese medicine, and health products [1] - On May 20, the net inflow of main funds was 11.79 million yuan, while the net outflow of speculative funds was 18.14 million yuan, and the net inflow of retail investors was 6.35 million yuan [3] Group 2 - Jiutian Pharmaceutical announced an adjustment of the conversion price for the bond "Jiutian Convertible Bond 02" from 15.33 yuan/share to 15.02 yuan/share, effective from May 26, 2025 [2][3] - The company plans to distribute a cash dividend of 3.129649 yuan per 10 shares to all shareholders, with a per-share cash dividend ratio of 0.3098112 yuan/share after the distribution [2]

Group 1 - The company announced an adjustment to the conversion price of its convertible bonds "九典转 02" due to its 2024 profit distribution plan [1][2] - The adjusted conversion price is set at 15.02 yuan per share, effective from May 26, 2025 [3] - The profit distribution plan includes a cash dividend of 0.3098112 yuan per share, with no stock dividends or capital increases [2][3] Group 2 - The company will follow specific formulas for adjusting the conversion price based on changes in share capital, including stock dividends, capital increases, and cash dividends [1][2] - The adjustment will be disclosed in a public announcement, detailing the adjustment date and method [2]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-039 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于九典转 02 转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 增发新股或配股：P1=（P0+A×k）/（1+k）； 1、债券代码：123223；债券简称：九典转 02 2、调整前转股价格：人民币 15.33 元/股 3、调整后转股价格：人民币 15.02 元/股 4、转股价格调整生效日期：2025 年 5 月 26 日 上述两项同时进行：P1=（P0+A×k）/（1+n+k）； 派送现金股利：P1=P0-D； 上述三项同时进行：P1=（P0-D+A×k）/（1+n+k）。 其中：P1 为调整后转股价，P0 为调整前转股价，n 为送股或转增股本率，A 为增发新股价或配股价，k 为增发新股或配股率，D 为每股派送现金股利。 当公司出现上述股份和/或股东权益变化情况时，将依 ...